Principal Investigator
Estelamari Rodriguez
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230700
Clinical Trial Summary
S2302, Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase
Phase III
Funding Agency/Sponsor
National Cooperative Group
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647